Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
XAIR Stock Forecast 2026-2027
$1.70
Current Price
$13.62M
Market Cap
Buy 3
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to XAIR Price Targets
+723.5%
To High Target of $14.00
+547.1%
To Median Target of $11.00
+252.9%
To Low Target of $6.00
XAIR Price Momentum
+93.2%
1 Week Change
+86.8%
1 Month Change
-79.6%
1 Year Change
+132.9%
Year-to-Date Change
-83.7%
From 52W High of $10.40
+152.6%
From 52W Low of $0.67
📊 TOP ANALYST CALLS
Did XAIR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Beyond Air is one of their latest high-conviction picks.
Latest XAIR Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, XAIR has a bullish consensus with a median price target of $11.00 (ranging from $6.00 to $14.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $1.70, the median forecast implies a 547.1% upside. This outlook is supported by 3 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Gregory Fraser at Truist Securities, projecting a 723.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XAIR Analyst Ratings
3
Buy
1
Hold
0
Sell
XAIR Price Target Range
Low
$6.00
Average
$11.00
High
$14.00
Current: $1.70
Latest XAIR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XAIR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 11, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $11.00 |
| Aug 21, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $11.00 |
| Aug 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $11.00 |
| Jul 17, 2025 | D. Boral Capital | Jason Kolbert | Buy | Initiates | $11.00 |
| Aug 16, 2024 | Roth MKM | Jason White | Buy | Reinstates | $2.00 |
| Aug 7, 2024 | Piper Sandler | Jason Bednar | Overweight | Maintains | $1.00 |
| Jun 25, 2024 | BTIG | Marie Thibault | Neutral | Downgrade | $N/A |
| Jun 25, 2024 | Piper Sandler | Jason Bednar | Overweight | Maintains | $3.50 |
| Apr 30, 2024 | Truist Securities | Gregory Fraser | Buy | Maintains | $8.00 |
| Nov 14, 2023 | Truist Securities | Gregory Fraser | Buy | Maintains | $10.00 |
| Jul 28, 2023 | Piper Sandler | Jason Bednar | Overweight | Initiates | $10.00 |
| Jul 21, 2023 | Truist Securities | Gregory Fraser | Buy | Maintains | $14.00 |
| Jun 23, 2023 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $10.00 |
| Jun 15, 2023 | BTIG | Buy | Initiates | $N/A | |
| Jun 29, 2022 | Ladenburg Thalmann | Matthew Kaplan | Buy | Maintains | $23.00 |
| Jun 29, 2022 | Truist Securities | Gregory Fraser | Buy | Maintains | $20.00 |
| Nov 12, 2021 | Truist Securities | Gregory Fraser | Buy | Maintains | $16.00 |
| Apr 28, 2021 | Truist Securities | Buy | Initiates | $N/A | |
| Oct 22, 2019 | Oppenheimer | Outperform | Initiates | $N/A |
Beyond Air, Inc. (XAIR) Competitors
The following stocks are similar to Beyond Air based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Beyond Air, Inc. (XAIR) Financial Data
Beyond Air, Inc. has a market capitalization of $13.62M with a P/E ratio of -0.1x. The company generates $5.80M in trailing twelve-month revenue with a -44.9% profit margin.
Revenue growth is +127.8% quarter-over-quarter, while maintaining an operating margin of -421.4% and return on equity of -178.0%.
Valuation Metrics
Market Cap
$13.62M
Enterprise Value
$18.52M
P/E Ratio
-0.1x
PEG Ratio
0.0x
Price/Sales
2.4x
Growth & Margins
Revenue Growth (YoY)
+127.8%
Gross Margin
-16.4%
Operating Margin
-421.4%
Net Margin
-44.9%
EPS Growth
+127.8%
Financial Health
Cash/Price Ratio
+78.5%
Current Ratio
4.2x
Debt/Equity
105.4x
ROE
-178.0%
ROA
-49.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Beyond Air, Inc. (XAIR) Business Model
About Beyond Air, Inc.
What They Do
Develops nitric oxide therapy solutions.
Business Model
Beyond Air, Inc. operates as a clinical-stage medical device and biopharmaceutical company that generates revenue through its innovative LungFit platform, which provides on-demand nitric oxide therapy for various medical conditions. The company markets devices like LungFit PH, LungFit PRO, and LungFit GO, targeting specific health issues such as pulmonary hypertension, viral lung infections, and nontuberculous mycobacteria infections.
Additional Information
Beyond Air is committed to enhancing respiratory and neurological healthcare through its patented technology and product offerings. The company also explores advanced therapeutics for treating solid tumors and neurological disorders, positioning itself at the intersection of innovative medical devices and biopharmaceuticals, backed by a knowledgeable leadership team.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
61
CEO
Mr. Steven Adam Lisi
Country
United States
IPO Year
2018
Website
www.beyondair.netBeyond Air, Inc. (XAIR) Latest News & Analysis
Latest News
Quick Summary
Two Nobel Laureates join Prof. Haitham Amal in autism research as FDA designations are secured for related conditions. Beyond Air (NASDAQ: XAIR) to gain 19.99% stake in XTL post-transaction.
Why It Matters
The collaboration with Nobel Laureates and FDA designations highlights potential breakthroughs in autism treatment, creating significant market opportunities for Beyond Air and XTL Biopharmaceuticals.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Beyond Air, Inc. (NASDAQ: XAIR) announced the resignation of CFO Doug Larson to pursue another opportunity, as of November 26, 2025.
Why It Matters
Doug Larson's resignation as CFO may indicate potential instability in financial leadership, which can affect investor confidence and stock performance for Beyond Air, Inc.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Beyond Air, Inc. (XAIR) will host its Q2 2026 earnings call on November 10, 2025, at 4:30 PM EST, discussing financial results for the quarter ended September 30, 2025.
Why It Matters
The earnings call for Beyond Air, Inc. will provide insights into the company's financial performance, strategies, and future outlook, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
2 months ago
Quick Summary
Revenue increased 128% YoY to $1.8M. Appointed Bob Goodman as Interim CCO. Raised $12M in debt; total cash and equivalents at $22.9M. FY 2026 revenue guidance updated to $8-10M. Conference call at 4:30 PM ET today.
Why It Matters
Revenue growth of 128% signals strong demand and operational success. The financing boost and MDSAP certification enhance financial stability and market credibility, while updated guidance suggests positive future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Beyond Air, Inc. (NASDAQ: XAIR) CFO Douglas Larson will speak at the ROTH 4th Annual Healthcare Opportunities Conference on October 9, 2025, in New York.
Why It Matters
Douglas Larson's participation in the ROTH Healthcare Conference may indicate upcoming developments or strategies that could influence Beyond Air's financial performance and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Beyond Air, Inc. announced a definitive agreement for the immediate exercise of warrants to purchase 1,439,126 shares at $2.21 each, generating approximately $3.25 million in gross proceeds.
Why It Matters
Beyond Air's warrant exercise indicates strong investor confidence and provides $3.25 million in capital, potentially funding growth and innovation, influencing stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About XAIR Stock
What is Beyond Air, Inc.'s (XAIR) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Beyond Air, Inc. (XAIR) has a median price target of $11.00. The highest price target is $14.00 and the lowest is $6.00.
Is XAIR stock a good investment in 2026?
According to current analyst ratings, XAIR has 3 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XAIR stock?
Wall Street analysts predict XAIR stock could reach $11.00 in the next 12 months. This represents a 547.1% increase from the current price of $1.70. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Beyond Air, Inc.'s business model?
Beyond Air, Inc. operates as a clinical-stage medical device and biopharmaceutical company that generates revenue through its innovative LungFit platform, which provides on-demand nitric oxide therapy for various medical conditions. The company markets devices like LungFit PH, LungFit PRO, and LungFit GO, targeting specific health issues such as pulmonary hypertension, viral lung infections, and nontuberculous mycobacteria infections.
What is the highest forecasted price for XAIR Beyond Air, Inc.?
The highest price target for XAIR is $14.00 from Gregory Fraser at Truist Securities, which represents a 723.5% increase from the current price of $1.70.
What is the lowest forecasted price for XAIR Beyond Air, Inc.?
The lowest price target for XAIR is $6.00 from at , which represents a 252.9% increase from the current price of $1.70.
What is the overall XAIR consensus from analysts for Beyond Air, Inc.?
The overall analyst consensus for XAIR is bullish. Out of 8 Wall Street analysts, 3 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $11.00.
How accurate are XAIR stock price projections?
Stock price projections, including those for Beyond Air, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 18, 2026 7:26 PM UTC